Skip to main content

Table 1 Baseline characteristics at the start of treatment

From: Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice

  HBeAg-positive HBeAg-negative
Number of patients: N (%) 7 (25%) 21 (75%)
Age (years)a 24 (8) 33 (7)
Male sex: N (%) 5 (71.4%) 19 (90.5%)
Mean length of stay in Spain (months)a 11 (72) 69 (28)
Co-morbidities None Coinfection with S. mansoni (2 patients) Fatty liver (1 patient)
ALT (IU/L)a 84 (61) 64.5 (119)
AST (IU/L)a 62 (26) 56.5 (93)
GGT (IU/L)a 30 (41) 48.5 (34)
ALP (IU/L)a 104 (66) 92 (35)
Total bilirubin (mg/dL)a 0.4 (0.2) 0.66 (0.93)
Platelets × 103 μLa 204 (97) 168.5 (111)
Prothrombin time (%)a 78 (18) 90.5 (20.3)
Alpha-fetoprotein (ng/mL)a 4.6 (3.6) 2.5 (1.4)
HBV-DNA (log IU/mL)a 7.23 (5.23) 5.28 (6.26)
FIB- 4 scorea 0.8 (1.8) 1.5 (0.9)
APRI scorea 0.9 (1.2) 1 (1.7)
Chosen treatment Tenofovir (7 patients) Tenofovir (17 patients) Entecavir (4 patients)
  1. aValues are median and (IQR). ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase, ALP Alkaline phosphatase. FIB-4 score: Fibrosis-4 score. APRI score: AST to Platelet Ratio Index